Palbociclib is an oral selective inhibitor of cyclin-dependent kinase( CDK) 4 and 6,which can restore the control of cell cycle and block the proliferation of tumor cells. In February 2015,palbociclib was approved by the accelerated approval process of the US FDA,and indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor( ER)-positive,human epidermal growth factor receptor 2( HER2)-negative advanced breast cancer as initial endocrine-based therapy for their ...
| 
推荐 
点击下列相关研究机构和相关文献作者，可以直接查到这些机构和作者被《中国知识资源总库》收录的其它文献，使您全面了解该机构和该作者的研究动态和历史。
